The Greater Cannabis Company, Inc.
The Greater Cannabis Company, Inc. (GCAN) Stock Competitors & Peer Comparison
See (GCAN) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| GCAN | $0.00 | -50.00% | 97.5K | N/A | N/A | N/A |
| MKKGY | $25.20 | -3.69% | 56.2B | 16.73 | $1.52 | +1.97% |
| MKGAF | $128.83 | -4.18% | 54.8B | 16.57 | $7.61 | +1.90% |
| HLNCF | $4.89 | -2.98% | 44.9B | 23.81 | $0.21 | +1.73% |
| TKPHF | $27.50 | +2.61% | 43B | 59.46 | $0.46 | +4.97% |
| IPSEY | $32.22 | -0.40% | 42.6B | 25.57 | $1.26 | +0.80% |
| SDZNY | $57.24 | -3.12% | 25.3B | -2932.50 | -$0.02 | +1.14% |
| ESALY | $61.51 | -2.11% | 17.6B | 20.54 | $3.00 | N/A |
| TEVJF | $14.00 | +0.00% | 16.1B | -12.17 | -$1.15 | N/A |
| SGIOY | $8.35 | -0.48% | 14.3B | 12.55 | $0.67 | +1.88% |
Stock Comparison
GCAN vs MKKGY Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, MKKGY has a market cap of 56.2B. Regarding current trading prices, GCAN is priced at $0.00, while MKKGY trades at $25.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas MKKGY's P/E ratio is 16.73. In terms of profitability, GCAN's ROE is +0.40%, compared to MKKGY's ROE of +0.10%. Regarding short-term risk, GCAN is less volatile compared to MKKGY. This indicates potentially lower risk in terms of short-term price fluctuations for GCAN.Check MKKGY's competition here
GCAN vs MKGAF Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, MKGAF has a market cap of 54.8B. Regarding current trading prices, GCAN is priced at $0.00, while MKGAF trades at $128.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas MKGAF's P/E ratio is 16.57. In terms of profitability, GCAN's ROE is +0.40%, compared to MKGAF's ROE of +0.10%. Regarding short-term risk, GCAN is less volatile compared to MKGAF. This indicates potentially lower risk in terms of short-term price fluctuations for GCAN.Check MKGAF's competition here
GCAN vs HLNCF Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, HLNCF has a market cap of 44.9B. Regarding current trading prices, GCAN is priced at $0.00, while HLNCF trades at $4.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas HLNCF's P/E ratio is 23.81. In terms of profitability, GCAN's ROE is +0.40%, compared to HLNCF's ROE of +0.09%. Regarding short-term risk, GCAN is less volatile compared to HLNCF. This indicates potentially lower risk in terms of short-term price fluctuations for GCAN.Check HLNCF's competition here
GCAN vs TKPHF Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, TKPHF has a market cap of 43B. Regarding current trading prices, GCAN is priced at $0.00, while TKPHF trades at $27.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas TKPHF's P/E ratio is 59.46. In terms of profitability, GCAN's ROE is +0.40%, compared to TKPHF's ROE of +0.01%. Regarding short-term risk, GCAN and TKPHF have similar daily volatility (0.00).Check TKPHF's competition here
GCAN vs IPSEY Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, IPSEY has a market cap of 42.6B. Regarding current trading prices, GCAN is priced at $0.00, while IPSEY trades at $32.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas IPSEY's P/E ratio is 25.57. In terms of profitability, GCAN's ROE is +0.40%, compared to IPSEY's ROE of +0.17%. Regarding short-term risk, GCAN and IPSEY have similar daily volatility (0.00).Check IPSEY's competition here
GCAN vs SDZNY Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, SDZNY has a market cap of 25.3B. Regarding current trading prices, GCAN is priced at $0.00, while SDZNY trades at $57.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas SDZNY's P/E ratio is -2932.50. In terms of profitability, GCAN's ROE is +0.40%, compared to SDZNY's ROE of +0.00%. Regarding short-term risk, GCAN is less volatile compared to SDZNY. This indicates potentially lower risk in terms of short-term price fluctuations for GCAN.Check SDZNY's competition here
GCAN vs ESALY Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, ESALY has a market cap of 17.6B. Regarding current trading prices, GCAN is priced at $0.00, while ESALY trades at $61.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas ESALY's P/E ratio is 20.54. In terms of profitability, GCAN's ROE is +0.40%, compared to ESALY's ROE of +0.06%. Regarding short-term risk, GCAN is less volatile compared to ESALY. This indicates potentially lower risk in terms of short-term price fluctuations for GCAN.Check ESALY's competition here
GCAN vs TEVJF Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, TEVJF has a market cap of 16.1B. Regarding current trading prices, GCAN is priced at $0.00, while TEVJF trades at $14.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas TEVJF's P/E ratio is -12.17. In terms of profitability, GCAN's ROE is +0.40%, compared to TEVJF's ROE of -0.21%. Regarding short-term risk, GCAN is less volatile compared to TEVJF. This indicates potentially lower risk in terms of short-term price fluctuations for GCAN.Check TEVJF's competition here
GCAN vs SGIOY Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, SGIOY has a market cap of 14.3B. Regarding current trading prices, GCAN is priced at $0.00, while SGIOY trades at $8.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas SGIOY's P/E ratio is 12.55. In terms of profitability, GCAN's ROE is +0.40%, compared to SGIOY's ROE of +0.05%. Regarding short-term risk, GCAN is less volatile compared to SGIOY. This indicates potentially lower risk in terms of short-term price fluctuations for GCAN.Check SGIOY's competition here
GCAN vs SGIOF Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, SGIOF has a market cap of 14.3B. Regarding current trading prices, GCAN is priced at $0.00, while SGIOF trades at $16.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas SGIOF's P/E ratio is 12.35. In terms of profitability, GCAN's ROE is +0.40%, compared to SGIOF's ROE of +0.05%. Regarding short-term risk, GCAN and SGIOF have similar daily volatility (0.00).Check SGIOF's competition here
GCAN vs BIOVF Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, BIOVF has a market cap of 10.3B. Regarding current trading prices, GCAN is priced at $0.00, while BIOVF trades at $29.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas BIOVF's P/E ratio is 22.57. In terms of profitability, GCAN's ROE is +0.40%, compared to BIOVF's ROE of +0.10%. Regarding short-term risk, GCAN and BIOVF have similar daily volatility (0.00).Check BIOVF's competition here
GCAN vs SFOSF Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, SFOSF has a market cap of 10.2B. Regarding current trading prices, GCAN is priced at $0.00, while SFOSF trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas SFOSF's P/E ratio is 17.80. In terms of profitability, GCAN's ROE is +0.40%, compared to SFOSF's ROE of +0.06%. Regarding short-term risk, GCAN and SFOSF have similar daily volatility (0.00).Check SFOSF's competition here
GCAN vs IPSEF Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, IPSEF has a market cap of 9.4B. Regarding current trading prices, GCAN is priced at $0.00, while IPSEF trades at $113.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas IPSEF's P/E ratio is 22.54. In terms of profitability, GCAN's ROE is +0.40%, compared to IPSEF's ROE of +0.14%. Regarding short-term risk, GCAN is less volatile compared to IPSEF. This indicates potentially lower risk in terms of short-term price fluctuations for GCAN.Check IPSEF's competition here
GCAN vs ESAIY Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, ESAIY has a market cap of 7.9B. Regarding current trading prices, GCAN is priced at $0.00, while ESAIY trades at $7.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas ESAIY's P/E ratio is 24.95. In terms of profitability, GCAN's ROE is +0.40%, compared to ESAIY's ROE of +0.03%. Regarding short-term risk, GCAN is less volatile compared to ESAIY. This indicates potentially lower risk in terms of short-term price fluctuations for GCAN.Check ESAIY's competition here
GCAN vs ESALF Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, ESALF has a market cap of 7.3B. Regarding current trading prices, GCAN is priced at $0.00, while ESALF trades at $27.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas ESALF's P/E ratio is 23.24. In terms of profitability, GCAN's ROE is +0.40%, compared to ESALF's ROE of +0.03%. Regarding short-term risk, GCAN and ESALF have similar daily volatility (0.00).Check ESALF's competition here
GCAN vs HKMPY Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, HKMPY has a market cap of 5.9B. Regarding current trading prices, GCAN is priced at $0.00, while HKMPY trades at $53.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas HKMPY's P/E ratio is 16.54. In terms of profitability, GCAN's ROE is +0.40%, compared to HKMPY's ROE of +0.16%. Regarding short-term risk, GCAN and HKMPY have similar daily volatility (0.00).Check HKMPY's competition here
GCAN vs GZPHF Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, GZPHF has a market cap of 5.8B. Regarding current trading prices, GCAN is priced at $0.00, while GZPHF trades at $2.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas GZPHF's P/E ratio is 10.22. In terms of profitability, GCAN's ROE is +0.40%, compared to GZPHF's ROE of +0.07%. Regarding short-term risk, GCAN is less volatile compared to GZPHF. This indicates potentially lower risk in terms of short-term price fluctuations for GCAN.Check GZPHF's competition here
GCAN vs HKMPF Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, HKMPF has a market cap of 5.8B. Regarding current trading prices, GCAN is priced at $0.00, while HKMPF trades at $26.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas HKMPF's P/E ratio is 16.38. In terms of profitability, GCAN's ROE is +0.40%, compared to HKMPF's ROE of +0.16%. Regarding short-term risk, GCAN and HKMPF have similar daily volatility (0.00).Check HKMPF's competition here
GCAN vs SGFEF Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, SGFEF has a market cap of 5.2B. Regarding current trading prices, GCAN is priced at $0.00, while SGFEF trades at $114.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas SGFEF's P/E ratio is 24.70. In terms of profitability, GCAN's ROE is +0.40%, compared to SGFEF's ROE of +0.11%. Regarding short-term risk, GCAN is less volatile compared to SGFEF. This indicates potentially lower risk in terms of short-term price fluctuations for GCAN.Check SGFEF's competition here
GCAN vs WIBFF Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, WIBFF has a market cap of 5B. Regarding current trading prices, GCAN is priced at $0.00, while WIBFF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas WIBFF's P/E ratio is -0.01. In terms of profitability, GCAN's ROE is +0.40%, compared to WIBFF's ROE of +0.00%. Regarding short-term risk, GCAN is less volatile compared to WIBFF. This indicates potentially lower risk in terms of short-term price fluctuations for GCAN.Check WIBFF's competition here
GCAN vs HLUBF Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, HLUBF has a market cap of 4.4B. Regarding current trading prices, GCAN is priced at $0.00, while HLUBF trades at $4.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas HLUBF's P/E ratio is 9.13. In terms of profitability, GCAN's ROE is +0.40%, compared to HLUBF's ROE of +0.14%. Regarding short-term risk, GCAN and HLUBF have similar daily volatility (0.00).Check HLUBF's competition here
GCAN vs HLBBF Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, HLBBF has a market cap of 4.1B. Regarding current trading prices, GCAN is priced at $0.00, while HLBBF trades at $5.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas HLBBF's P/E ratio is 9.90. In terms of profitability, GCAN's ROE is +0.40%, compared to HLBBF's ROE of +0.14%. Regarding short-term risk, GCAN is less volatile compared to HLBBF. This indicates potentially lower risk in terms of short-term price fluctuations for GCAN.Check HLBBF's competition here
GCAN vs CHSYF Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, CHSYF has a market cap of 3.7B. Regarding current trading prices, GCAN is priced at $0.00, while CHSYF trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas CHSYF's P/E ratio is 16.85. In terms of profitability, GCAN's ROE is +0.40%, compared to CHSYF's ROE of +0.09%. Regarding short-term risk, GCAN and CHSYF have similar daily volatility (0.00).Check CHSYF's competition here
GCAN vs ULIHF Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, ULIHF has a market cap of 3.6B. Regarding current trading prices, GCAN is priced at $0.00, while ULIHF trades at $1.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas ULIHF's P/E ratio is 9.25. In terms of profitability, GCAN's ROE is +0.40%, compared to ULIHF's ROE of +0.21%. Regarding short-term risk, GCAN is less volatile compared to ULIHF. This indicates potentially lower risk in terms of short-term price fluctuations for GCAN.Check ULIHF's competition here
GCAN vs LVZPF Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, LVZPF has a market cap of 3.4B. Regarding current trading prices, GCAN is priced at $0.00, while LVZPF trades at $3.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas LVZPF's P/E ratio is 11.43. In terms of profitability, GCAN's ROE is +0.40%, compared to LVZPF's ROE of +0.15%. Regarding short-term risk, GCAN is less volatile compared to LVZPF. This indicates potentially lower risk in terms of short-term price fluctuations for GCAN.Check LVZPF's competition here
GCAN vs APNHF Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, APNHF has a market cap of 3.2B. Regarding current trading prices, GCAN is priced at $0.00, while APNHF trades at $7.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas APNHF's P/E ratio is 12.72. In terms of profitability, GCAN's ROE is +0.40%, compared to APNHF's ROE of +0.04%. Regarding short-term risk, GCAN is less volatile compared to APNHF. This indicates potentially lower risk in terms of short-term price fluctuations for GCAN.Check APNHF's competition here
GCAN vs SMDPY Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, SMDPY has a market cap of 3B. Regarding current trading prices, GCAN is priced at $0.00, while SMDPY trades at $9.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas SMDPY's P/E ratio is 19.15. In terms of profitability, GCAN's ROE is +0.40%, compared to SMDPY's ROE of +0.15%. Regarding short-term risk, GCAN and SMDPY have similar daily volatility (0.00).Check SMDPY's competition here
GCAN vs APNHY Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, APNHY has a market cap of 3B. Regarding current trading prices, GCAN is priced at $0.00, while APNHY trades at $6.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas APNHY's P/E ratio is 11.93. In terms of profitability, GCAN's ROE is +0.40%, compared to APNHY's ROE of +0.05%. Regarding short-term risk, GCAN is less volatile compared to APNHY. This indicates potentially lower risk in terms of short-term price fluctuations for GCAN.Check APNHY's competition here
GCAN vs INVVY Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, INVVY has a market cap of 3B. Regarding current trading prices, GCAN is priced at $0.00, while INVVY trades at $21.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas INVVY's P/E ratio is -62.42. In terms of profitability, GCAN's ROE is +0.40%, compared to INVVY's ROE of -0.01%. Regarding short-term risk, GCAN and INVVY have similar daily volatility (0.00).Check INVVY's competition here
GCAN vs IZQVF Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, IZQVF has a market cap of 2.9B. Regarding current trading prices, GCAN is priced at $0.00, while IZQVF trades at $20.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas IZQVF's P/E ratio is -56.68. In terms of profitability, GCAN's ROE is +0.40%, compared to IZQVF's ROE of -0.01%. Regarding short-term risk, GCAN and IZQVF have similar daily volatility (0.00).Check IZQVF's competition here
GCAN vs DNPUF Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, DNPUF has a market cap of 2.9B. Regarding current trading prices, GCAN is priced at $0.00, while DNPUF trades at $7.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas DNPUF's P/E ratio is 18.10. In terms of profitability, GCAN's ROE is +0.40%, compared to DNPUF's ROE of +0.15%. Regarding short-term risk, GCAN is less volatile compared to DNPUF. This indicates potentially lower risk in terms of short-term price fluctuations for GCAN.Check DNPUF's competition here
GCAN vs LBTSF Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, LBTSF has a market cap of 2.9B. Regarding current trading prices, GCAN is priced at $0.00, while LBTSF trades at $13.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas LBTSF's P/E ratio is 111.33. In terms of profitability, GCAN's ROE is +0.40%, compared to LBTSF's ROE of +0.02%. Regarding short-term risk, GCAN and LBTSF have similar daily volatility (0.00).Check LBTSF's competition here
GCAN vs HYPMY Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, HYPMY has a market cap of 2.8B. Regarding current trading prices, GCAN is priced at $0.00, while HYPMY trades at $4.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas HYPMY's P/E ratio is 19.39. In terms of profitability, GCAN's ROE is +0.40%, compared to HYPMY's ROE of +0.07%. Regarding short-term risk, GCAN and HYPMY have similar daily volatility (0.00).Check HYPMY's competition here
GCAN vs HMDCF Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, HMDCF has a market cap of 2.8B. Regarding current trading prices, GCAN is priced at $0.00, while HMDCF trades at $3.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas HMDCF's P/E ratio is -64.10. In terms of profitability, GCAN's ROE is +0.40%, compared to HMDCF's ROE of -0.01%. Regarding short-term risk, GCAN and HMDCF have similar daily volatility (0.00).Check HMDCF's competition here
GCAN vs THCBF Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, THCBF has a market cap of 2.4B. Regarding current trading prices, GCAN is priced at $0.00, while THCBF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas THCBF's P/E ratio is -0.10. In terms of profitability, GCAN's ROE is +0.40%, compared to THCBF's ROE of +0.00%. Regarding short-term risk, GCAN is less volatile compared to THCBF. This indicates potentially lower risk in terms of short-term price fluctuations for GCAN.Check THCBF's competition here
GCAN vs DMPHF Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, DMPHF has a market cap of 2.1B. Regarding current trading prices, GCAN is priced at $0.00, while DMPHF trades at $39.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas DMPHF's P/E ratio is 17.90. In terms of profitability, GCAN's ROE is +0.40%, compared to DMPHF's ROE of +0.17%. Regarding short-term risk, GCAN and DMPHF have similar daily volatility (0.00).Check DMPHF's competition here
GCAN vs HTSUF Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, HTSUF has a market cap of 2.1B. Regarding current trading prices, GCAN is priced at $0.00, while HTSUF trades at $28.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas HTSUF's P/E ratio is 16.08. In terms of profitability, GCAN's ROE is +0.40%, compared to HTSUF's ROE of +0.08%. Regarding short-term risk, GCAN is less volatile compared to HTSUF. This indicates potentially lower risk in terms of short-term price fluctuations for GCAN.Check HTSUF's competition here
GCAN vs LJUIF Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, LJUIF has a market cap of 2.1B. Regarding current trading prices, GCAN is priced at $0.00, while LJUIF trades at $0.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas LJUIF's P/E ratio is 13.97. In terms of profitability, GCAN's ROE is +0.40%, compared to LJUIF's ROE of +0.19%. Regarding short-term risk, GCAN and LJUIF have similar daily volatility (0.00).Check LJUIF's competition here
GCAN vs ARSUF Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, ARSUF has a market cap of 1.8B. Regarding current trading prices, GCAN is priced at $0.00, while ARSUF trades at $25.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas ARSUF's P/E ratio is 22.70. In terms of profitability, GCAN's ROE is +0.40%, compared to ARSUF's ROE of +0.16%. Regarding short-term risk, GCAN and ARSUF have similar daily volatility (0.00).Check ARSUF's competition here
GCAN vs TSMRF Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, TSMRF has a market cap of 1.8B. Regarding current trading prices, GCAN is priced at $0.00, while TSMRF trades at $23.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas TSMRF's P/E ratio is 8.21. In terms of profitability, GCAN's ROE is +0.40%, compared to TSMRF's ROE of +0.11%. Regarding short-term risk, GCAN and TSMRF have similar daily volatility (0.00).Check TSMRF's competition here
GCAN vs YIHCF Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, YIHCF has a market cap of 1.8B. Regarding current trading prices, GCAN is priced at $0.00, while YIHCF trades at $0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas YIHCF's P/E ratio is -5.00. In terms of profitability, GCAN's ROE is +0.40%, compared to YIHCF's ROE of +0.19%. Regarding short-term risk, GCAN and YIHCF have similar daily volatility (0.00).Check YIHCF's competition here
GCAN vs NPNKF Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, NPNKF has a market cap of 1.7B. Regarding current trading prices, GCAN is priced at $0.00, while NPNKF trades at $25.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas NPNKF's P/E ratio is 7.82. In terms of profitability, GCAN's ROE is +0.40%, compared to NPNKF's ROE of +0.14%. Regarding short-term risk, GCAN is less volatile compared to NPNKF. This indicates potentially lower risk in terms of short-term price fluctuations for GCAN.Check NPNKF's competition here
GCAN vs CASBF Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, CASBF has a market cap of 1.6B. Regarding current trading prices, GCAN is priced at $0.00, while CASBF trades at $5.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas CASBF's P/E ratio is -25.33. In terms of profitability, GCAN's ROE is +0.40%, compared to CASBF's ROE of -0.14%. Regarding short-term risk, GCAN and CASBF have similar daily volatility (0.00).Check CASBF's competition here
GCAN vs MITPF Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, MITPF has a market cap of 1.6B. Regarding current trading prices, GCAN is priced at $0.00, while MITPF trades at $23.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas MITPF's P/E ratio is -10.81. In terms of profitability, GCAN's ROE is +0.40%, compared to MITPF's ROE of +4.92%. Regarding short-term risk, GCAN is less volatile compared to MITPF. This indicates potentially lower risk in terms of short-term price fluctuations for GCAN.Check MITPF's competition here
GCAN vs KARBF Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, KARBF has a market cap of 1.5B. Regarding current trading prices, GCAN is priced at $0.00, while KARBF trades at $5.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas KARBF's P/E ratio is 262.50. In terms of profitability, GCAN's ROE is +0.40%, compared to KARBF's ROE of N/A. Regarding short-term risk, GCAN and KARBF have similar daily volatility (0.00).Check KARBF's competition here
GCAN vs EVOTF Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, EVOTF has a market cap of 1.5B. Regarding current trading prices, GCAN is priced at $0.00, while EVOTF trades at $8.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas EVOTF's P/E ratio is -6.17. In terms of profitability, GCAN's ROE is +0.40%, compared to EVOTF's ROE of -0.22%. Regarding short-term risk, GCAN is less volatile compared to EVOTF. This indicates potentially lower risk in terms of short-term price fluctuations for GCAN.Check EVOTF's competition here
GCAN vs GTBIF Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, GTBIF has a market cap of 1.4B. Regarding current trading prices, GCAN is priced at $0.00, while GTBIF trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas GTBIF's P/E ratio is 28.49. In terms of profitability, GCAN's ROE is +0.40%, compared to GTBIF's ROE of +0.03%. Regarding short-term risk, GCAN is less volatile compared to GTBIF. This indicates potentially lower risk in terms of short-term price fluctuations for GCAN.Check GTBIF's competition here
GCAN vs SHEZF Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, SHEZF has a market cap of 1.4B. Regarding current trading prices, GCAN is priced at $0.00, while SHEZF trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas SHEZF's P/E ratio is -23.48. In terms of profitability, GCAN's ROE is +0.40%, compared to SHEZF's ROE of +0.05%. Regarding short-term risk, GCAN is less volatile compared to SHEZF. This indicates potentially lower risk in terms of short-term price fluctuations for GCAN.Check SHEZF's competition here
GCAN vs NPPNY Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, NPPNY has a market cap of 1.4B. Regarding current trading prices, GCAN is priced at $0.00, while NPPNY trades at $5.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas NPPNY's P/E ratio is 6.35. In terms of profitability, GCAN's ROE is +0.40%, compared to NPPNY's ROE of +0.09%. Regarding short-term risk, GCAN and NPPNY have similar daily volatility (0.00).Check NPPNY's competition here
GCAN vs CHIZF Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, CHIZF has a market cap of 1.4B. Regarding current trading prices, GCAN is priced at $0.00, while CHIZF trades at $0.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas CHIZF's P/E ratio is 13.75. In terms of profitability, GCAN's ROE is +0.40%, compared to CHIZF's ROE of +0.04%. Regarding short-term risk, GCAN and CHIZF have similar daily volatility (0.00).Check CHIZF's competition here
GCAN vs GNMLF Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, GNMLF has a market cap of 1.2B. Regarding current trading prices, GCAN is priced at $0.00, while GNMLF trades at $1.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas GNMLF's P/E ratio is 11.70. In terms of profitability, GCAN's ROE is +0.40%, compared to GNMLF's ROE of +0.12%. Regarding short-term risk, GCAN and GNMLF have similar daily volatility (0.00).Check GNMLF's competition here
GCAN vs SWGHF Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, SWGHF has a market cap of 1.1B. Regarding current trading prices, GCAN is priced at $0.00, while SWGHF trades at $11.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas SWGHF's P/E ratio is 15.57. In terms of profitability, GCAN's ROE is +0.40%, compared to SWGHF's ROE of +0.12%. Regarding short-term risk, GCAN and SWGHF have similar daily volatility (0.00).Check SWGHF's competition here
GCAN vs KSPHF Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, KSPHF has a market cap of 1.1B. Regarding current trading prices, GCAN is priced at $0.00, while KSPHF trades at $27.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas KSPHF's P/E ratio is 14.59. In terms of profitability, GCAN's ROE is +0.40%, compared to KSPHF's ROE of +0.06%. Regarding short-term risk, GCAN and KSPHF have similar daily volatility (0.00).Check KSPHF's competition here
GCAN vs CURLF Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, CURLF has a market cap of 1.1B. Regarding current trading prices, GCAN is priced at $0.00, while CURLF trades at $1.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas CURLF's P/E ratio is -4.18. In terms of profitability, GCAN's ROE is +0.40%, compared to CURLF's ROE of -0.25%. Regarding short-term risk, GCAN is less volatile compared to CURLF. This indicates potentially lower risk in terms of short-term price fluctuations for GCAN.Check CURLF's competition here
GCAN vs KKPCF Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, KKPCF has a market cap of 1B. Regarding current trading prices, GCAN is priced at $0.00, while KKPCF trades at $28.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas KKPCF's P/E ratio is 11.24. In terms of profitability, GCAN's ROE is +0.40%, compared to KKPCF's ROE of +0.09%. Regarding short-term risk, GCAN is less volatile compared to KKPCF. This indicates potentially lower risk in terms of short-term price fluctuations for GCAN.Check KKPCF's competition here
GCAN vs BIOGY Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, BIOGY has a market cap of 960.3M. Regarding current trading prices, GCAN is priced at $0.00, while BIOGY trades at $9.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas BIOGY's P/E ratio is 32.50. In terms of profitability, GCAN's ROE is +0.40%, compared to BIOGY's ROE of +0.18%. Regarding short-term risk, GCAN and BIOGY have similar daily volatility (0.00).Check BIOGY's competition here
GCAN vs SHPHF Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, SHPHF has a market cap of 924.4M. Regarding current trading prices, GCAN is priced at $0.00, while SHPHF trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas SHPHF's P/E ratio is -3.33. In terms of profitability, GCAN's ROE is +0.40%, compared to SHPHF's ROE of -0.01%. Regarding short-term risk, GCAN is less volatile compared to SHPHF. This indicates potentially lower risk in terms of short-term price fluctuations for GCAN.Check SHPHF's competition here
GCAN vs LVTTF Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, LVTTF has a market cap of 893.4M. Regarding current trading prices, GCAN is priced at $0.00, while LVTTF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas LVTTF's P/E ratio is -0.02. In terms of profitability, GCAN's ROE is +0.40%, compared to LVTTF's ROE of +0.00%. Regarding short-term risk, GCAN is less volatile compared to LVTTF. This indicates potentially lower risk in terms of short-term price fluctuations for GCAN.Check LVTTF's competition here
GCAN vs EVRRF Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, EVRRF has a market cap of 889.6M. Regarding current trading prices, GCAN is priced at $0.00, while EVRRF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas EVRRF's P/E ratio is -0.08. In terms of profitability, GCAN's ROE is +0.40%, compared to EVRRF's ROE of +2.97%. Regarding short-term risk, GCAN and EVRRF have similar daily volatility (0.00).Check EVRRF's competition here
GCAN vs TCNNF Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, TCNNF has a market cap of 886.6M. Regarding current trading prices, GCAN is priced at $0.00, while TCNNF trades at $4.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas TCNNF's P/E ratio is -5.87. In terms of profitability, GCAN's ROE is +0.40%, compared to TCNNF's ROE of -0.13%. Regarding short-term risk, GCAN is less volatile compared to TCNNF. This indicates potentially lower risk in terms of short-term price fluctuations for GCAN.Check TCNNF's competition here
GCAN vs NRXCF Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, NRXCF has a market cap of 844.1M. Regarding current trading prices, GCAN is priced at $0.00, while NRXCF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas NRXCF's P/E ratio is -0.22. In terms of profitability, GCAN's ROE is +0.40%, compared to NRXCF's ROE of +2.32%. Regarding short-term risk, GCAN and NRXCF have similar daily volatility (0.00).Check NRXCF's competition here
GCAN vs TWAPF Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, TWAPF has a market cap of 828.5M. Regarding current trading prices, GCAN is priced at $0.00, while TWAPF trades at $16.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas TWAPF's P/E ratio is 6.28. In terms of profitability, GCAN's ROE is +0.40%, compared to TWAPF's ROE of +0.11%. Regarding short-term risk, GCAN and TWAPF have similar daily volatility (0.00).Check TWAPF's competition here
GCAN vs SWDCF Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, SWDCF has a market cap of 773.6M. Regarding current trading prices, GCAN is priced at $0.00, while SWDCF trades at $4.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas SWDCF's P/E ratio is 121.00. In terms of profitability, GCAN's ROE is +0.40%, compared to SWDCF's ROE of +0.01%. Regarding short-term risk, GCAN is less volatile compared to SWDCF. This indicates potentially lower risk in terms of short-term price fluctuations for GCAN.Check SWDCF's competition here
GCAN vs CSWYF Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, CSWYF has a market cap of 758.4M. Regarding current trading prices, GCAN is priced at $0.00, while CSWYF trades at $1.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas CSWYF's P/E ratio is 4.78. In terms of profitability, GCAN's ROE is +0.40%, compared to CSWYF's ROE of +0.07%. Regarding short-term risk, GCAN is less volatile compared to CSWYF. This indicates potentially lower risk in terms of short-term price fluctuations for GCAN.Check CSWYF's competition here
GCAN vs TRXPF Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, TRXPF has a market cap of 690.7M. Regarding current trading prices, GCAN is priced at $0.00, while TRXPF trades at $24.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas TRXPF's P/E ratio is 25.86. In terms of profitability, GCAN's ROE is +0.40%, compared to TRXPF's ROE of +0.04%. Regarding short-term risk, GCAN and TRXPF have similar daily volatility (0.00).Check TRXPF's competition here
GCAN vs TRSSF Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, TRSSF has a market cap of 601.9M. Regarding current trading prices, GCAN is priced at $0.00, while TRSSF trades at $1.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas TRSSF's P/E ratio is -1.32. In terms of profitability, GCAN's ROE is +0.40%, compared to TRSSF's ROE of -0.32%. Regarding short-term risk, GCAN is less volatile compared to TRSSF. This indicates potentially lower risk in terms of short-term price fluctuations for GCAN.Check TRSSF's competition here
GCAN vs ELTP Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, ELTP has a market cap of 566.4M. Regarding current trading prices, GCAN is priced at $0.00, while ELTP trades at $0.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas ELTP's P/E ratio is -26.45. In terms of profitability, GCAN's ROE is +0.40%, compared to ELTP's ROE of -0.09%. Regarding short-term risk, GCAN is less volatile compared to ELTP. This indicates potentially lower risk in terms of short-term price fluctuations for GCAN.Check ELTP's competition here
GCAN vs PKBFF Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, PKBFF has a market cap of 544.4M. Regarding current trading prices, GCAN is priced at $0.00, while PKBFF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas PKBFF's P/E ratio is N/A. In terms of profitability, GCAN's ROE is +0.40%, compared to PKBFF's ROE of +7.96%. Regarding short-term risk, GCAN and PKBFF have similar daily volatility (0.00).Check PKBFF's competition here
GCAN vs AIHLF Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, AIHLF has a market cap of 543.1M. Regarding current trading prices, GCAN is priced at $0.00, while AIHLF trades at $3.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas AIHLF's P/E ratio is 12.50. In terms of profitability, GCAN's ROE is +0.40%, compared to AIHLF's ROE of +0.15%. Regarding short-term risk, GCAN and AIHLF have similar daily volatility (0.00).Check AIHLF's competition here
GCAN vs CCHWF Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, CCHWF has a market cap of 521.3M. Regarding current trading prices, GCAN is priced at $0.00, while CCHWF trades at $0.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas CCHWF's P/E ratio is -1.12. In terms of profitability, GCAN's ROE is +0.40%, compared to CCHWF's ROE of -7.05%. Regarding short-term risk, GCAN is less volatile compared to CCHWF. This indicates potentially lower risk in terms of short-term price fluctuations for GCAN.Check CCHWF's competition here
GCAN vs BOIRF Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, BOIRF has a market cap of 494.8M. Regarding current trading prices, GCAN is priced at $0.00, while BOIRF trades at $28.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas BOIRF's P/E ratio is 20.07. In terms of profitability, GCAN's ROE is +0.40%, compared to BOIRF's ROE of +0.06%. Regarding short-term risk, GCAN and BOIRF have similar daily volatility (0.00).Check BOIRF's competition here
GCAN vs PEXXF Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, PEXXF has a market cap of 463.1M. Regarding current trading prices, GCAN is priced at $0.00, while PEXXF trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas PEXXF's P/E ratio is 9.00. In terms of profitability, GCAN's ROE is +0.40%, compared to PEXXF's ROE of N/A. Regarding short-term risk, GCAN and PEXXF have similar daily volatility (0.00).Check PEXXF's competition here
GCAN vs KHTRF Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, KHTRF has a market cap of 446.4M. Regarding current trading prices, GCAN is priced at $0.00, while KHTRF trades at $4.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas KHTRF's P/E ratio is 64.00. In terms of profitability, GCAN's ROE is +0.40%, compared to KHTRF's ROE of +0.01%. Regarding short-term risk, GCAN and KHTRF have similar daily volatility (0.00).Check KHTRF's competition here
GCAN vs AGYTF Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, AGYTF has a market cap of 405.1M. Regarding current trading prices, GCAN is priced at $0.00, while AGYTF trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas AGYTF's P/E ratio is -8.50. In terms of profitability, GCAN's ROE is +0.40%, compared to AGYTF's ROE of -2.67%. Regarding short-term risk, GCAN is less volatile compared to AGYTF. This indicates potentially lower risk in terms of short-term price fluctuations for GCAN.Check AGYTF's competition here
GCAN vs HUMDF Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, HUMDF has a market cap of 404M. Regarding current trading prices, GCAN is priced at $0.00, while HUMDF trades at $0.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas HUMDF's P/E ratio is -13.69. In terms of profitability, GCAN's ROE is +0.40%, compared to HUMDF's ROE of +8.06%. Regarding short-term risk, GCAN and HUMDF have similar daily volatility (0.00).Check HUMDF's competition here
GCAN vs NIKA Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, NIKA has a market cap of 366.9M. Regarding current trading prices, GCAN is priced at $0.00, while NIKA trades at $0.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas NIKA's P/E ratio is N/A. In terms of profitability, GCAN's ROE is +0.40%, compared to NIKA's ROE of +0.39%. Regarding short-term risk, GCAN and NIKA have similar daily volatility (0.00).Check NIKA's competition here
GCAN vs GLASF Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, GLASF has a market cap of 277.4M. Regarding current trading prices, GCAN is priced at $0.00, while GLASF trades at $5.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas GLASF's P/E ratio is -57.44. In terms of profitability, GCAN's ROE is +0.40%, compared to GLASF's ROE of +0.07%. Regarding short-term risk, GCAN is less volatile compared to GLASF. This indicates potentially lower risk in terms of short-term price fluctuations for GCAN.Check GLASF's competition here
GCAN vs BHCCF Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, BHCCF has a market cap of 271.6M. Regarding current trading prices, GCAN is priced at $0.00, while BHCCF trades at $0.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas BHCCF's P/E ratio is -4.57. In terms of profitability, GCAN's ROE is +0.40%, compared to BHCCF's ROE of +0.19%. Regarding short-term risk, GCAN is less volatile compared to BHCCF. This indicates potentially lower risk in terms of short-term price fluctuations for GCAN.Check BHCCF's competition here
GCAN vs CPHRF Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, CPHRF has a market cap of 225.7M. Regarding current trading prices, GCAN is priced at $0.00, while CPHRF trades at $8.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas CPHRF's P/E ratio is 24.47. In terms of profitability, GCAN's ROE is +0.40%, compared to CPHRF's ROE of +0.09%. Regarding short-term risk, GCAN is less volatile compared to CPHRF. This indicates potentially lower risk in terms of short-term price fluctuations for GCAN.Check CPHRF's competition here
GCAN vs VRNOF Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, VRNOF has a market cap of 212.2M. Regarding current trading prices, GCAN is priced at $0.00, while VRNOF trades at $0.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas VRNOF's P/E ratio is -0.59. In terms of profitability, GCAN's ROE is +0.40%, compared to VRNOF's ROE of -0.22%. Regarding short-term risk, GCAN is less volatile compared to VRNOF. This indicates potentially lower risk in terms of short-term price fluctuations for GCAN.Check VRNOF's competition here
GCAN vs CRLBF Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, CRLBF has a market cap of 210.7M. Regarding current trading prices, GCAN is priced at $0.00, while CRLBF trades at $0.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas CRLBF's P/E ratio is -2.60. In terms of profitability, GCAN's ROE is +0.40%, compared to CRLBF's ROE of -0.18%. Regarding short-term risk, GCAN is less volatile compared to CRLBF. This indicates potentially lower risk in terms of short-term price fluctuations for GCAN.Check CRLBF's competition here
GCAN vs PLNHF Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, PLNHF has a market cap of 202M. Regarding current trading prices, GCAN is priced at $0.00, while PLNHF trades at $0.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas PLNHF's P/E ratio is -3.50. In terms of profitability, GCAN's ROE is +0.40%, compared to PLNHF's ROE of -0.34%. Regarding short-term risk, GCAN is less volatile compared to PLNHF. This indicates potentially lower risk in terms of short-term price fluctuations for GCAN.Check PLNHF's competition here
GCAN vs PHCUF Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, PHCUF has a market cap of 159.9M. Regarding current trading prices, GCAN is priced at $0.00, while PHCUF trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas PHCUF's P/E ratio is 600.00. In terms of profitability, GCAN's ROE is +0.40%, compared to PHCUF's ROE of +0.00%. Regarding short-term risk, GCAN and PHCUF have similar daily volatility (0.00).Check PHCUF's competition here
GCAN vs CBWTF Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, CBWTF has a market cap of 135.4M. Regarding current trading prices, GCAN is priced at $0.00, while CBWTF trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas CBWTF's P/E ratio is 5.07. In terms of profitability, GCAN's ROE is +0.40%, compared to CBWTF's ROE of -0.15%. Regarding short-term risk, GCAN is less volatile compared to CBWTF. This indicates potentially lower risk in terms of short-term price fluctuations for GCAN.Check CBWTF's competition here
GCAN vs COPHF Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, COPHF has a market cap of 131.7M. Regarding current trading prices, GCAN is priced at $0.00, while COPHF trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas COPHF's P/E ratio is -0.02. In terms of profitability, GCAN's ROE is +0.40%, compared to COPHF's ROE of -5.75%. Regarding short-term risk, GCAN is less volatile compared to COPHF. This indicates potentially lower risk in terms of short-term price fluctuations for GCAN.Check COPHF's competition here
GCAN vs STMH Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, STMH has a market cap of 125.9M. Regarding current trading prices, GCAN is priced at $0.00, while STMH trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas STMH's P/E ratio is N/A. In terms of profitability, GCAN's ROE is +0.40%, compared to STMH's ROE of -2.75%. Regarding short-term risk, GCAN and STMH have similar daily volatility (0.00).Check STMH's competition here
GCAN vs LOVFF Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, LOVFF has a market cap of 124.3M. Regarding current trading prices, GCAN is priced at $0.00, while LOVFF trades at $1.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas LOVFF's P/E ratio is 13.60. In terms of profitability, GCAN's ROE is +0.40%, compared to LOVFF's ROE of +0.15%. Regarding short-term risk, GCAN is less volatile compared to LOVFF. This indicates potentially lower risk in terms of short-term price fluctuations for GCAN.Check LOVFF's competition here
GCAN vs NWPN Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, NWPN has a market cap of 123.7M. Regarding current trading prices, GCAN is priced at $0.00, while NWPN trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas NWPN's P/E ratio is -0.04. In terms of profitability, GCAN's ROE is +0.40%, compared to NWPN's ROE of +0.13%. Regarding short-term risk, GCAN is less volatile compared to NWPN. This indicates potentially lower risk in terms of short-term price fluctuations for GCAN.Check NWPN's competition here
GCAN vs HLTRF Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, HLTRF has a market cap of 112.4M. Regarding current trading prices, GCAN is priced at $0.00, while HLTRF trades at $3.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas HLTRF's P/E ratio is -6.26. In terms of profitability, GCAN's ROE is +0.40%, compared to HLTRF's ROE of -0.24%. Regarding short-term risk, GCAN and HLTRF have similar daily volatility (0.00).Check HLTRF's competition here
GCAN vs JUSHF Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, JUSHF has a market cap of 111.2M. Regarding current trading prices, GCAN is priced at $0.00, while JUSHF trades at $0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas JUSHF's P/E ratio is -2.26. In terms of profitability, GCAN's ROE is +0.40%, compared to JUSHF's ROE of +1.06%. Regarding short-term risk, GCAN is less volatile compared to JUSHF. This indicates potentially lower risk in terms of short-term price fluctuations for GCAN.Check JUSHF's competition here
GCAN vs LPCUF Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, LPCUF has a market cap of 110.8M. Regarding current trading prices, GCAN is priced at $0.00, while LPCUF trades at $0.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas LPCUF's P/E ratio is 18.82. In terms of profitability, GCAN's ROE is +0.40%, compared to LPCUF's ROE of +0.05%. Regarding short-term risk, GCAN and LPCUF have similar daily volatility (0.00).Check LPCUF's competition here
GCAN vs CNVCF Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, CNVCF has a market cap of 109.2M. Regarding current trading prices, GCAN is priced at $0.00, while CNVCF trades at $6.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas CNVCF's P/E ratio is -5.00. In terms of profitability, GCAN's ROE is +0.40%, compared to CNVCF's ROE of +9.56%. Regarding short-term risk, GCAN and CNVCF have similar daily volatility (0.00).Check CNVCF's competition here
GCAN vs AAWH Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, AAWH has a market cap of 96.1M. Regarding current trading prices, GCAN is priced at $0.00, while AAWH trades at $0.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas AAWH's P/E ratio is -1.17. In terms of profitability, GCAN's ROE is +0.40%, compared to AAWH's ROE of -1.05%. Regarding short-term risk, GCAN is less volatile compared to AAWH. This indicates potentially lower risk in terms of short-term price fluctuations for GCAN.Check AAWH's competition here
GCAN vs BIOYF Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, BIOYF has a market cap of 95.2M. Regarding current trading prices, GCAN is priced at $0.00, while BIOYF trades at $8.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas BIOYF's P/E ratio is 16.94. In terms of profitability, GCAN's ROE is +0.40%, compared to BIOYF's ROE of +0.22%. Regarding short-term risk, GCAN and BIOYF have similar daily volatility (0.00).Check BIOYF's competition here
GCAN vs GRUSF Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, GRUSF has a market cap of 94.2M. Regarding current trading prices, GCAN is priced at $0.00, while GRUSF trades at $0.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas GRUSF's P/E ratio is -12.67. In terms of profitability, GCAN's ROE is +0.40%, compared to GRUSF's ROE of -0.89%. Regarding short-term risk, GCAN is less volatile compared to GRUSF. This indicates potentially lower risk in terms of short-term price fluctuations for GCAN.Check GRUSF's competition here
GCAN vs CANSF Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, CANSF has a market cap of 91.3M. Regarding current trading prices, GCAN is priced at $0.00, while CANSF trades at $0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas CANSF's P/E ratio is -1.21. In terms of profitability, GCAN's ROE is +0.40%, compared to CANSF's ROE of -21.00%. Regarding short-term risk, GCAN and CANSF have similar daily volatility (0.00).Check CANSF's competition here
GCAN vs LRDSF Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, LRDSF has a market cap of 83.9M. Regarding current trading prices, GCAN is priced at $0.00, while LRDSF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas LRDSF's P/E ratio is -0.01. In terms of profitability, GCAN's ROE is +0.40%, compared to LRDSF's ROE of +1.61%. Regarding short-term risk, GCAN and LRDSF have similar daily volatility (0.00).Check LRDSF's competition here
GCAN vs ABSCF Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, ABSCF has a market cap of 77.4M. Regarding current trading prices, GCAN is priced at $0.00, while ABSCF trades at $1.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas ABSCF's P/E ratio is -7.00. In terms of profitability, GCAN's ROE is +0.40%, compared to ABSCF's ROE of +0.32%. Regarding short-term risk, GCAN is less volatile compared to ABSCF. This indicates potentially lower risk in terms of short-term price fluctuations for GCAN.Check ABSCF's competition here
GCAN vs EOFBY Comparison July 2025
GCAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCAN stands at 97.5K. In comparison, EOFBY has a market cap of 73.7M. Regarding current trading prices, GCAN is priced at $0.00, while EOFBY trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCAN currently has a P/E ratio of N/A, whereas EOFBY's P/E ratio is -7.67. In terms of profitability, GCAN's ROE is +0.40%, compared to EOFBY's ROE of N/A. Regarding short-term risk, GCAN and EOFBY have similar daily volatility (0.00).Check EOFBY's competition here